Thomas Ciulla, MD, Medical Strategy Lead, Ophthalmology at Spark Therapeutics Inc., tells OIS-TV why the retina is so challenging to fix. But gene therapy companies like Spark are showing promising signs.
Негізгі бет Ғылым және технология Spark’s Ciulla Says Luxturna Could Be Sign of Treatment to Come
Пікірлер: 4